TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...

Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...

Microsoft's CEO, Satya Nadella, has introduced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding protein motion.

Hiding in Plain Sight Quantum computing has surged from theoretical curiosity to a transformative frontier, promising to ...

TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpetual Medicines, which is advancing a ...

Researchers discovered how to flip the structure of complex drug compounds using a simple reagent, offering a game-changing ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...

A fundamental discovery by University of Missouri scientists could help solve one of the most frustrating challenges in ...